Fenoterol


Thông tin thuốc gốc
Chỉ định và Liều dùng
Inhalation/Respiratory
Prophylaxis of exercise-induced asthma, Reversible airways obstruction
Adult: As metered-dose inhaler (100 mcg/dose): 1-2 inhalations as needed. Max: 8 inhalations daily. As soln (50 mcg/drop): 0.5 mL (10 drops or 500 mcg) up to 4 times daily.

Inhalation/Respiratory
Acute asthma
Adult: As metered-dose inhaler (100 mcg/dose): 1 inhalation as needed, if symptoms are not adequately controlled after 5 min, a 2nd dose may be given. As soln (50 mcg/drop): 0.5 mL (10 drops or 500 mcg), may require higher doses between 1-1.25 mL (20-25 drops or 1,000-1,250 mcg) in severe cases.
Child: 6-12 yr 22-36 kg/body wt: As soln (50 mcg/drop): 0.25-0.5 mL (5-10 drops or 250-500 mcg). May require higher doses up to 1 mL (20 drops or 1,000 mcg) in severe cases.

Oral
Acute bronchospasm
Adult: 2.5-5 mg tid. Max: 15 mg daily.
Chống chỉ định
Hypertrophic obstructive cardiomyopathy, tachyarrhythmia.
Thận trọng
Patient w/ severe asthma, underlying severe heart disease (e.g. ischaemic heart disease, severe organic heart disease, arrhythmia, severe heart failure), insufficiently controlled DM, recent MI, hyperthyroidism, phaeochromocytoma, and severe vascular disorder. Pregnancy and lactation.
Phản ứng phụ
Hypokalaemia, hypersensitivity, nervousness, agitation, headache, dizziness, tremor, palpitations, myocardial ischaemia, tachycardia, arrhythmia, nausea, vomiting, hyperhidrosis, skin reactions (e.g. urticaria, rash, pruritus), myalgia, muscular weakness, muscle spasm, paradoxical bronchospasm, cough, throat irritation, increased systolic and decreased diastolic BP.
MonitoringParameters
Monitor serum K levels.
Quá liều
Symptoms: Palpitation, tachycardia, tremor, HTN, hypotension, widening of pulse pressure, anginal pain, arrhythmias, flushing, metabolic acidosis. Management: Admin of tranquilisers, sedatives in severe cases; β-receptor blockers preferably β1-selective. Intensive therapy may be required.
Tương tác
Increased effect w/ β-adrenergics, anticholinergics, MAOIs, TCAs and xanthine derivatives (e.g. theophylline). Serious reduction in bronchodilation w/ β-blockers. May enhance susceptibility to CV effects w/ halothane, enflurane, and trichloroethylene.
Tác dụng
Description: Fenoterol is a direct-acting sympathomimetic agent w/ predominant β-adrenoceptor stimulant activity largely selective for β2-receptors.
Onset: W/in a few min (inhalation).
Duration: Approx 3-5 hr (inhalation).
Pharmacokinetics:
Absorption: Incompletely absorbed from the GI tract.
Distribution: Enters breast milk.
Metabolism: Undergoes extensive first-pass metabolism via sulfate conjugation
Excretion: Via urine and bile (mainly as inactive sulfate conjugate).
Đặc tính

Chemical Structure Image
Fenoterol

Source: National Center for Biotechnology Information. PubChem Database. Fenoterol, CID=3343, https://pubchem.ncbi.nlm.nih.gov/compound/Fenoterol (accessed on Jan. 20, 2020)

Bảo quản
Store below 30°C.
Phân loại ATC
R03CC04 - fenoterol ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03AC04 - fenoterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
References
Anon. Fenoterol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 10/02/2016 .

Berotec. MIMS Indonesia. http://mims.com/indonesia. Accessed 10/02/2016 .

Buckingham R (ed). Fenoterol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/02/2016 .

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Fenoterol từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Berotec
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in